References
- Cheng AY, Fantus IG. Oral antihyperglycemic therapy for type 2 diabetes mellitus. CMAJ. 2005;172:213-226. https://doi.org/10.1503/cmaj.1031414
- Farret A, Lugo-Garcia L, Galtier F, Gross R, Petit P. Pharmacological interventions that directly stimulate or modulate insulin secretion from pancreatic beta-cell: implications for the treatment of type 2 diabetes. Fundam Clin Pharmacol. 2005; 19:647-656. https://doi.org/10.1111/j.1472-8206.2005.00375.x
- Horton ES, Clinkingbeard C, Gatlin M, Foley J, Mallows S, Shen S. Nateglinide alone and in combination with metformin improves glycemic control by reducing mealtime glucose levels in type 2 diabetes. Diabetes Care. 2000;23:1660-1665. https://doi.org/10.2337/diacare.23.11.1660
- Perfetti R, Barnett PS, Mathur R, Egan JM. Novel therapeutic strategies for the treatment of type 2 diabetes. Diabetes Metab Rev. 1998;14:207-225. https://doi.org/10.1002/(SICI)1099-0895(1998090)14:3<207::AID-DMR214>3.0.CO;2-J
- Sunaga Y, Gonoi T, Shibasaki T, Ichikawa K, Kusama H, Yano H, Seino S. The effects of mitiglinide (KAD-1229), a new anti-diabetic drug, on ATP-sensitive K+ channels and insulin secretion: comparison with the sulfonylureas and nateglinide. Eur J Pharmacol. 2001;431:119-125. https://doi.org/10.1016/S0014-2999(01)01412-1
- Bokvist K, Hoy M, Buschard K, Holst JJ, Thomsen MK, Gromada J. Selectivity of prandial glucose regulators: nateglinide, but not repaglinide, accelerates exocytosis in rat pancreatic A-cells. Eur J Pharmacol. 1999;386:105-111. https://doi.org/10.1016/S0014-2999(99)00754-2
- Bryan J, Crane A, Vila-Carriles WH, Babenko AP, Aguilar- Bryan L. Insulin secretagogues, sulfonylurea receptors and K(ATP) channels. Curr Pharm Des. 2005;11:2699-2716. https://doi.org/10.2174/1381612054546879
- Gribble FM, Reimann F. Differential selectivity of insulin secretagogues: mechanisms, clinical implications, and drug interactions. J Diabetes Complications. 2003;17(2 Suppl):11-15.
- Henquin JC. Pathways in beta-cell stimulus-secretion coupling as targets for therapeutic insulin secretagogues. Diabetes. 2004;53 Suppl 3:S48-58. https://doi.org/10.2337/diabetes.53.suppl_3.S48
- Islam MS. The ryanodine receptor calcium channel of betacells: molecular regulation and physiological significance. Diabetes. 2002;51:1299-1309. https://doi.org/10.2337/diabetes.51.5.1299
- Benzo CA. Minireview. The hypothalamus and blood glucose regulation. Life Sci. 1983;32:2509-2515. https://doi.org/10.1016/0024-3205(83)90231-X
- Ohnuma H, Yamatani K, Igarashi M, Sugiyama K, Manaka H, Tominaga M, Sasaki H. Intracerebroventricular injection of methylatropine suppresses insulin response to oral glucose load in rats. J Auton Nerv Syst. 1996;57:43-48. https://doi.org/10.1016/0165-1838(95)00101-8
- Petit F, Jarrous A, Dickinson RD, Molina PE, Abumrad NN, Lang CH. Contribution of central and peripheral adrenergic stimulation to IL-1 alpha-mediated glucoregulation. Am J Physiol. 1994;267:E49-56.
- Sala F, Menna G, Bricolo A, Young W. Role of glycemia in acute spinal cord injury. Data from a rat experimental model and clinical experience. Ann N Y Acad Sci. 1999;890:133-154. https://doi.org/10.1111/j.1749-6632.1999.tb07989.x
- Ritter S, Bugarith K, Dinh TT. Immunotoxic destruction of distinct catecholamine subgroups produces selective impairment of glucoregulatory responses and neuronal activation. J Comp Neurol. 2001;432:197-216. https://doi.org/10.1002/cne.1097
-
Sim YB, Park SH, Kang YJ, Jung JS, Ryu OH, Choi MG, Suh HW. Interleukin-1
$\beta$ (IL-1$\beta$ ) increases pain behavior and the blood glucose level: possible involvement of sympathetic nervous system. Pharmacol Biochem Behav. 2012;102:170-176. https://doi.org/10.1016/j.pbb.2012.04.006 - Sim YB, Park SH, Kang YJ, Jung JS, Ryu OH, Choi MG, Suh HW. Various pain stimulations cause an increase of the blood glucose level. Animal Cells and Systems. 2012;16:385-390. https://doi.org/10.1080/19768354.2012.696554
- Sim YB, Park SH, Kang YJ, Kim SS, Kim CH, Kim SJ, Jung JS, Ryu OH, Choi MG, Suh HW. Central anti-diabetic action of biguanide and thizolidinediones in D-glucose fed and streptozotocin- treated mouse models. Neurosci Lett. 2012;528:73-77. https://doi.org/10.1016/j.neulet.2012.08.038
- Hylden JL, Wilcox GL. Intrathecal substance P elicits a caudally-directed biting and scratching behavior in mice. Brain Res. 1981;217:212-215. https://doi.org/10.1016/0006-8993(81)90203-1
- Haley TJ. Pharmacological effects produced by intracerebral administration of drugs of unrelated structure to conscious mice. Arch Int Pharmacodyn Ther. 1957;110:239-244.
- Zhang Y, Zhou J, Corll C, Porter JR, Martin RJ, Roane DS. Evidence for hypothalamic K+(ATP) channels in the modulation of glucose homeostasis. Eur J Pharmacol. 2004;492:71-79. https://doi.org/10.1016/j.ejphar.2004.03.040
- Arison RN, Ciaccio EI, Glitzer MS, Cassaro JA, Pruss MP. Light and electron microscopy of lesions in rats rendered diabetic with streptozotocin. Diabetes. 1967;16:51-56. https://doi.org/10.2337/diab.16.1.51
- Mansford KR, Opie L. Comparison of metabolic abnormalities in diabetes mellitus induced by streptozotocin or by alloxan. Lancet. 1968;1:670-671.
Cited by
- Effects of nateglinide and repaglinide administered intracerebroventricularly on the CA3 hippocampal neuronal cell death and hyperglycemia induced by kainic acid in mice vol.104, pp.None, 2014, https://doi.org/10.1016/j.brainresbull.2014.02.003
- The modulatory roles of oxyntomodulin and glucagon-like peptide 1 administered spinally in the regulation of the blood glucose level vol.11, pp.1, 2013, https://doi.org/10.1134/s1819712416040115
- Spinal β-adrenergic receptors’ activation increases the blood glucose level in mice vol.21, pp.4, 2013, https://doi.org/10.1080/19768354.2017.1345788